Kyle Mikson
Stock Analyst at Canaccord Genuity
(1.93)
# 3,037
Out of 5,182 analysts
126
Total ratings
33.7%
Success rate
-6.4%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEER Seer, Inc. | Initiates: Buy | $4 | $2.03 | +97.04% | 1 | May 4, 2026 | |
| ILMN Illumina | Maintains: Hold | $150 → $140 | $135.78 | +3.11% | 16 | May 1, 2026 | |
| XGN Exagen | Maintains: Buy | $10 → $8 | $3.06 | +161.44% | 7 | Apr 20, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $170 → $100 | $65.38 | +52.95% | 4 | Apr 20, 2026 | |
| VCYT Veracyte | Maintains: Hold | $43 → $40 | $33.09 | +20.88% | 3 | Apr 20, 2026 | |
| TXG 10x Genomics | Maintains: Buy | $22 → $32 | $22.43 | +42.67% | 11 | Apr 20, 2026 | |
| RGEN Repligen | Maintains: Hold | $165 → $145 | $117.20 | +23.72% | 5 | Apr 20, 2026 | |
| QTRX Quanterix | Maintains: Hold | $8 → $4 | $3.40 | +17.65% | 9 | Apr 20, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $50 → $40 | $24.81 | +61.23% | 7 | Apr 20, 2026 | |
| CAI Caris Life Sciences | Maintains: Hold | $30 → $22 | $18.47 | +19.11% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $1.5 → $1 | $0.96 | +4.36% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $135 | $87.60 | +54.11% | 11 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $80 | $54.06 | +47.98% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $11.08 | +80.51% | 6 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $80 | $55.00 | +45.45% | 3 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 → $285 | $207.28 | +37.50% | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.60 | +87.50% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.09 | +175.23% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $2.43 | -17.70% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,476 | $8.53 | +17,203.63% | 1 | Mar 30, 2021 |
Seer, Inc.
May 4, 2026
Initiates: Buy
Price Target: $4
Current: $2.03
Upside: +97.04%
Illumina
May 1, 2026
Maintains: Hold
Price Target: $150 → $140
Current: $135.78
Upside: +3.11%
Exagen
Apr 20, 2026
Maintains: Buy
Price Target: $10 → $8
Current: $3.06
Upside: +161.44%
GeneDx Holdings
Apr 20, 2026
Maintains: Buy
Price Target: $170 → $100
Current: $65.38
Upside: +52.95%
Veracyte
Apr 20, 2026
Maintains: Hold
Price Target: $43 → $40
Current: $33.09
Upside: +20.88%
10x Genomics
Apr 20, 2026
Maintains: Buy
Price Target: $22 → $32
Current: $22.43
Upside: +42.67%
Repligen
Apr 20, 2026
Maintains: Hold
Price Target: $165 → $145
Current: $117.20
Upside: +23.72%
Quanterix
Apr 20, 2026
Maintains: Hold
Price Target: $8 → $4
Current: $3.40
Upside: +17.65%
Castle Biosciences
Apr 20, 2026
Maintains: Buy
Price Target: $50 → $40
Current: $24.81
Upside: +61.23%
Caris Life Sciences
Mar 13, 2026
Maintains: Hold
Price Target: $30 → $22
Current: $18.47
Upside: +19.11%
Mar 5, 2026
Maintains: Hold
Price Target: $1.5 → $1
Current: $0.96
Upside: +4.36%
Feb 20, 2026
Maintains: Buy
Price Target: $125 → $135
Current: $87.60
Upside: +54.11%
Feb 20, 2026
Maintains: Buy
Price Target: $105 → $80
Current: $54.06
Upside: +47.98%
Feb 17, 2026
Maintains: Buy
Price Target: $20
Current: $11.08
Upside: +80.51%
Dec 22, 2025
Maintains: Buy
Price Target: $95 → $80
Current: $55.00
Upside: +45.45%
Dec 22, 2025
Maintains: Buy
Price Target: $250 → $285
Current: $207.28
Upside: +37.50%
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.60
Upside: +87.50%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $1.09
Upside: +175.23%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $2.43
Upside: -17.70%
Mar 30, 2021
Initiates: Overweight
Price Target: $1,476
Current: $8.53
Upside: +17,203.63%